Raeisi Farzaneh, Abolfathi Mahdieh, Ahmadi-Naji Raheleh, Iranparast Sara, Noshadi Esmat, Akbari Arvand, Mahmoudi Esmaeil, Khaledi Mansoor, Arshi Asghar
Young Researchers and Elite Club, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran.
Department of Immunology, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Mol Biol Rep. 2019 Feb;46(1):77-82. doi: 10.1007/s11033-018-4447-6. Epub 2018 Oct 26.
Important regulatory roles of long non-coding RNAs (lncRNAs) have been recently found, and reported as useful biomarkers in cancer. To identify a potential expression of the new discovered lncRNA (ARA), during promotes cell proliferation, apoptosis inhibit, migration and cell cycle arrest, we firstly evaluate its expression in two cancer tissues (breast cancer and liver cancer) and then compared its variability expression in tumor versus non-tumor samples. Expression profile of ARA lncRNA was evaluated using qRT-PCR in paired tumor and marginal non-tumor samples collected from patients who had been referred to the Shiraz General. After RNA extraction from tissue samples, cDNA synthesis and RT-qPCR method were performed according to the protocols. ARA lncRNA expression level was calculated using 2 method. Principal-component analysis followed by receiver operating characteristic curve analyses was performed to evaluate the diagnostic potential of selected lncRNA. Our data revealed a significant upregulation (P < 0.001) of ARA in breast and liver tumor tissues, in comparison to same patients non-tumor marginal samples. Also, there was a significant difference between the expression of ARA lncRNA in breast cancer and liver cancer patients (P < 0.05). In conclusion, the results of our study suggest a possible role of ARA lncRNA in proliferation of breast and liver tissues, as well as its potential usefulness as a novel diagnostic biomarker for breast and liver tumors.
最近发现了长链非编码RNA(lncRNAs)的重要调控作用,并报道其可作为癌症的有用生物标志物。为了鉴定新发现的lncRNA(ARA)的潜在表达,其在促进细胞增殖、抑制凋亡、迁移和细胞周期停滞过程中的作用,我们首先评估其在两种癌组织(乳腺癌和肝癌)中的表达,然后比较其在肿瘤与非肿瘤样本中的差异表达。使用qRT-PCR评估ARA lncRNA在从转诊至设拉子综合医院的患者收集的配对肿瘤和边缘非肿瘤样本中的表达谱。从组织样本中提取RNA后,根据方案进行cDNA合成和RT-qPCR方法。使用2-△△CT方法计算ARA lncRNA表达水平。进行主成分分析,随后进行受试者工作特征曲线分析,以评估所选lncRNA的诊断潜力。我们的数据显示,与同一患者的非肿瘤边缘样本相比,ARA在乳腺和肝脏肿瘤组织中显著上调(P < 0.001)。此外,ARA lncRNA在乳腺癌和肝癌患者中的表达存在显著差异(P < 0.05)。总之,我们的研究结果表明ARA lncRNA在乳腺和肝脏组织增殖中可能发挥作用,以及其作为乳腺癌和肝癌新型诊断生物标志物的潜在用途。